Feedback

Molecular structures of cdc2-like kinases in complex with a new inhibitor chemotype

GND
1162466103
Affiliation/Institute
Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig
Walter, Anne; Chaikuad, Apirat;
GND
1162466170
Affiliation/Institute
Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig
Helmer, Renate; Loa͏ëc, Nadège;
GND
1132100763
Affiliation/Institute
Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig
Preu, Lutz;
GND
129456683
Affiliation/Institute
Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig
Ott, Ingo; Knapp, Stefan; Meijer, Laurent;
ORCID
0000-0001-7041-5322
Affiliation/Institute
Institut für Medizinische und Pharmazeutische Chemie, Technische Universität Braunschweig
Kunick, Conrad

Cdc2-like kinases (CLKs) represent a family of serine-threonine kinases involved in the regulation of splicing by phosphorylation of SR-proteins and other splicing factors. Although compounds acting against CLKs have been described, only a few show selectivity against dual-specificity tyrosine phosphorylation regulated-kinases (DYRKs). We here report a novel CLK inhibitor family based on a 6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one core scaffold. Within the series, 3-(3-chlorophenyl)-6,7-dihydropyrrolo[3,4-g]indol-8(1H)-one (KuWal151) was identified as inhibitor of CLK1, CLK2 and CLK4 with a high selectivity margin towards DYRK kinases. The compound displayed a potent antiproliferative activity in an array of cultured cancer cell lines. The X-ray structure analyses of three members of the new compound class co-crystallized with CLK proteins corroborated a molecular binding mode predicted by docking studies.

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

Use and reproduction: